Meningococcal B recombinant vaccine

A vaccine comprising an immunogenic composition comprising a combination of Neisseria meningitidis serogroup B antigens, said combination consisting of:

• (i) a 25 to 100 μg/dose of at least one non-lipidated factor H binding protein (fHBP) A protein comprising at least about 85% identity with SEQ ID NO:
• 1 and comprising at least the amino acid substitution G220S based on the numbering of SEQ ID NO:
• 6;
• (ii) a 25 to 100 μg/dose of at least one non-lipidated fHBP B protein consisting of SEQ ID NO:
• 4, with the proviso that the N-terminal cysteine of SEQ ID NO:
• 4 is removed or substituted with another amino acid;
• (iii) a 25 to 100 μg/dose of at least one Neisseria adhesin A (NadA) protein consisting of SEQ ID NO:
• 5;
• and
• (iv) a 20 to 150 μg/dose of at least one detergent-extracted Outer Membrane Vesicle (dOMV) from a MenB strain expressing PorA,
• wherein the vaccine further comprises 100 to 600 μg/dose of aluminum phosphate adjuvant, and 50 mM acetate buffer, wherein the composition has a pH of 6.0.